Health CarePharmaceuticals & Biotechnology
  • Price (GBX)547.50
  • Today's Change11.50 / 2.15%
  • Shares traded176.16k
  • 1 Year change2.15%
  • Beta0.8746
Data delayed at least 20 minutes, as of Aug 24 2016 17:10 BST.
More ▼

Forecasts data is unavailable for this security.

Consensus recommendation

Analyst consensus information is not available for GW Pharmaceuticals plc.
  • 1yr ago
Select bar for recommendation details.

Earnings history & estimates

On Dec 07, 2015, GW Pharmaceuticals plc reported 4th quarter 2015 losses of -0.047 per share. This result under-performed the breakeven expectation of the 3 analysts following the company but under-performed last year's 4th quarter results by -0.048.
The next earnings announcement is expected on Dec 05, 2016.
Average growth rate-83.16%
GW Pharmaceuticals plc reported annual 2015 losses of -0.181 per share on Dec 07, 2015.
The next earnings announcement from GW Pharmaceuticals plc is expected the week of Dec 05, 2016.
Average growth rate-100.63%
More ▼

Revenue history & estimates

GW Pharmaceuticals plc had 4th quarter 2015 revenues of 5.60m. This missed the 18.33m consensus estimate of the 3 analysts following the company. The same period last year the company did not report revenues.
Average growth rate-35.16%
GW Pharmaceuticals plc had revenues for the full year 2015 of 28.54m. This was 5.01% below the prior year's results.
Average growth rate-0.18%
More ▼
© Thomson Reuters Click for restrictions
All markets data located on is subject to the FT Terms & Conditions
All content on is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.